Endometrial Cancer Trial Fails, but Myelofibrosis sNDA Filed with Promising Data
KPTI is trading near its 52-week low of $1.8 (8.8% above the low) on elevated volume (24× avg).
Summary
Karyopharm's Phase 3 XPORT-EC-042 trial in endometrial cancer missed its primary PFS endpoint, a major setback for the selinexor pipeline. However, the company has filed an sNDA for myelofibrosis based on the SENTRY trial, which showed SVR35 at week 24, rapid spleen responses, and an overall survival signal. HC Wainwright downgraded the stock to Neutral and slashed its price target to $3 from $13, reflecting reduced confidence. This follows the July 30 news of the trial failure and the July 31 8-K outlining plans for the sNDA and financing exploration. With a market cap near $43 million and a cash runway only into late Q3 2026, the myelofibrosis sNDA acceptance and potential approval are critical for survival.
At the time of this announcement, KPTI was trading at $1.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.5M. The 52-week trading range was $1.80 to $10.99. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.